Accord Resumes Production of Cancer Drug in Short Supply

Accord Healthcare has resumed manufacturing of methotrexate, one of the most commonly used cancer drugs, in a move that could help ease shortages in the US.

The Food and Drug Administration reported that production had resumed. The generic-drug manufacturer didn’t immediately respond to a request for comment.

Methotrexate is a chemotherapy medicine injected to treat a variety of cancers, including breast and lung cancer, and acute lymphoblastic leukemia in children. It works by impeding the growth of cancer cells and suppressing the immune system. Shortages have been caused in part by a disruption in supply due to quality problems at ...